Literature DB >> 22498579

Value of PAX 8 immunostaining in tumor diagnosis: a review and update.

Nelson G Ordóñez1.   

Abstract

PAX 8 is a transcription factor involved in the regulation of organogenesis of the thyroid gland, kidney, and Müllerian system. Recent studies have shown that, among tumors, PAX 8 is commonly expressed in epithelial tumors of the thyroid and parathyroid glands, kidney, thymus, and female genital tract. Although PAX 8 expression has also been reported in certain neuroendocrine tumors, including well-differentiated pancreatic neuroendocrine tumors, and duodenal and rectal carcinoids, as well as in B-cell lymphomas, it has recently been shown that the PAX 8 positivity reported in these tumors was due to a cross-reactivity of the antibody used with the N-terminal region of PAX 6 and PAX 5, respectively. Owing to its restricted expression, PAX 8 has proved to be a useful immunohistochemical marker with a wide range of diagnostic applications in surgical pathology, some of which are briefly reviewed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22498579     DOI: 10.1097/PAP.0b013e318253465d

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  29 in total

1.  Thyroid-like low-grade papillary adenocarcinoma of nasopharynx.

Authors:  Ainaz Sourati; Mona Malekzadeh; Azadeh Rakhshan
Journal:  BMJ Case Rep       Date:  2019-06-08

2.  High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.

Authors:  Yali Zhai; Rong Wu; Rork Kuick; Michael S Sessine; Stephanie Schulman; Megan Green; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2017-07-25       Impact factor: 7.996

Review 3.  Prognostic biomarkers in endometrial and ovarian carcinoma.

Authors:  Xavier Matias-Guiu; Ben Davidson
Journal:  Virchows Arch       Date:  2014-02-07       Impact factor: 4.064

4.  PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?

Authors:  Meaghan L Barr; Lucia B Jilaveanu; Robert L Camp; Adebowale J Adeniran; Harriet M Kluger; Brian Shuch
Journal:  J Clin Pathol       Date:  2014-10-14       Impact factor: 3.411

5.  Long non-coding RNA PAX8-AS1 polymorphisms increase the risk of childhood acute lymphoblastic leukemia.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Simin Sadeghi-Bojd; Mohsen Taheri
Journal:  Biomed Rep       Date:  2017-12-13

Review 6.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

7.  Evaluation of PAX8 Expression and Its Potential Diagnostic and Prognostic Value in Renal and Extra-Renal Ewing Sarcomas/PNETs.

Authors:  Michael Markow; Marilyn M Bui; Hui-Yi Lin; Mark Lloyd; Wade J Sexton; Jasreman Dhillon
Journal:  Pathol Oncol Res       Date:  2015-09-09       Impact factor: 3.201

8.  Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms.

Authors:  Randall T Butler; Megan A Alderman; Lester D R Thompson; Jonathan B McHugh
Journal:  Head Neck Pathol       Date:  2014-04-26

9.  PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.

Authors:  Dima Ghannam-Shahbari; Eyal Jacob; Reli Rachel Kakun; Tanya Wasserman; Lina Korsensky; Ofir Sternfeld; Juliana Kagan; Debora Rosa Bublik; Sarit Aviel-Ronen; Keren Levanon; Edmond Sabo; Sarit Larisch; Moshe Oren; Dov Hershkovitz; Ruth Perets
Journal:  Oncogene       Date:  2018-01-30       Impact factor: 9.867

10.  Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.

Authors:  Willemina R R Geurts-Giele; Victorien M T van Verschuer; Carolien H M van Deurzen; Paul J van Diest; Rute M S M Pedrosa; J Margriet Collée; Linetta B Koppert; Caroline Seynaeve; Winand N M Dinjens
Journal:  Mod Pathol       Date:  2016-09-09       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.